Cargando…

First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates

AIM: The aim of the following study is to evaluate adherence and compliance of postmenopausal osteoporotic patients for different regimens of bisphosphonates (BP). MATERIALS AND METHODS: A prospective observational randomized comparative 1 year study was undertaken to evaluate the adherence/complian...

Descripción completa

Detalles Bibliográficos
Autores principales: Tandon, Vishal R., Sharma, Sudhaa, Mahajan, Shagun, Mahajan, Annil, Khajuria, Vijay, Gillani, Zahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955042/
https://www.ncbi.nlm.nih.gov/pubmed/24672203
http://dx.doi.org/10.4103/0976-7800.127788
_version_ 1782307529354641408
author Tandon, Vishal R.
Sharma, Sudhaa
Mahajan, Shagun
Mahajan, Annil
Khajuria, Vijay
Gillani, Zahid
author_facet Tandon, Vishal R.
Sharma, Sudhaa
Mahajan, Shagun
Mahajan, Annil
Khajuria, Vijay
Gillani, Zahid
author_sort Tandon, Vishal R.
collection PubMed
description AIM: The aim of the following study is to evaluate adherence and compliance of postmenopausal osteoporotic patients for different regimens of bisphosphonates (BP). MATERIALS AND METHODS: A prospective observational randomized comparative 1 year study was undertaken to evaluate the adherence/compliance rates of most commonly prescribed daily alendronate (ALN), weekly risedronate (RIS) and monthly ibandronate (IBN) BP regimens. RESULTS: Nearly 40% was the 1 year adherence rate with BP and 41.33% of non-compliance. Whereas, 8.66% was interrupted compliance rate and 6% switched over to other anti-osteoporotic treatment. The three treatment arm did not vary significantly. However, numerically maximum adherence rate of 56% was recorded in monthly BP regimen followed by weekly (36%) and daily regimen (32%). Medication possession rate confirmed on a follow-up visit was maximum with monthly regimen as 84.61% followed by daily (62.5%) and weekly (61.11%) respectively. Average time in days for non-adherence was 48, 56 and 92 day with daily ALN, weekly RIS and monthly IBN regimen respectively. Age, mean age at menopause, demographical profile failed to influence the adherence. Concomitant treatment for co-morbid condition (57.14%), unawareness about osteoporosis (OP) (50%), cost of treatment (45.33%), belief that drugs is for their general disability (39.28%), physician's failure to stress the need and necessary calcium + vitamin D daily requirement (23.80%) each were the most prevalent factors responsible for non-adherence. Intolerance and adverse drug reactions were responsible for only 13.09% and 11.90% of non-adherence. CONCLUSION: Treatment compliance is poor with daily ALN, weekly RIS and monthly IBN regimen along with calcium and vitamin D3 in Indian paramedical workers suffering OP.
format Online
Article
Text
id pubmed-3955042
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39550422014-03-26 First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates Tandon, Vishal R. Sharma, Sudhaa Mahajan, Shagun Mahajan, Annil Khajuria, Vijay Gillani, Zahid J Midlife Health Original Article AIM: The aim of the following study is to evaluate adherence and compliance of postmenopausal osteoporotic patients for different regimens of bisphosphonates (BP). MATERIALS AND METHODS: A prospective observational randomized comparative 1 year study was undertaken to evaluate the adherence/compliance rates of most commonly prescribed daily alendronate (ALN), weekly risedronate (RIS) and monthly ibandronate (IBN) BP regimens. RESULTS: Nearly 40% was the 1 year adherence rate with BP and 41.33% of non-compliance. Whereas, 8.66% was interrupted compliance rate and 6% switched over to other anti-osteoporotic treatment. The three treatment arm did not vary significantly. However, numerically maximum adherence rate of 56% was recorded in monthly BP regimen followed by weekly (36%) and daily regimen (32%). Medication possession rate confirmed on a follow-up visit was maximum with monthly regimen as 84.61% followed by daily (62.5%) and weekly (61.11%) respectively. Average time in days for non-adherence was 48, 56 and 92 day with daily ALN, weekly RIS and monthly IBN regimen respectively. Age, mean age at menopause, demographical profile failed to influence the adherence. Concomitant treatment for co-morbid condition (57.14%), unawareness about osteoporosis (OP) (50%), cost of treatment (45.33%), belief that drugs is for their general disability (39.28%), physician's failure to stress the need and necessary calcium + vitamin D daily requirement (23.80%) each were the most prevalent factors responsible for non-adherence. Intolerance and adverse drug reactions were responsible for only 13.09% and 11.90% of non-adherence. CONCLUSION: Treatment compliance is poor with daily ALN, weekly RIS and monthly IBN regimen along with calcium and vitamin D3 in Indian paramedical workers suffering OP. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC3955042/ /pubmed/24672203 http://dx.doi.org/10.4103/0976-7800.127788 Text en Copyright: © Journal of Mid-life Health http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Tandon, Vishal R.
Sharma, Sudhaa
Mahajan, Shagun
Mahajan, Annil
Khajuria, Vijay
Gillani, Zahid
First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
title First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
title_full First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
title_fullStr First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
title_full_unstemmed First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
title_short First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
title_sort first indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955042/
https://www.ncbi.nlm.nih.gov/pubmed/24672203
http://dx.doi.org/10.4103/0976-7800.127788
work_keys_str_mv AT tandonvishalr firstindianprospectiverandomizedcomparativestudyevaluatingadherenceandcomplianceofpostmenopausalosteoporoticpatientsfordailyalendronateweeklyrisedronateandmonthlyibandronateregimensofbisphosphonates
AT sharmasudhaa firstindianprospectiverandomizedcomparativestudyevaluatingadherenceandcomplianceofpostmenopausalosteoporoticpatientsfordailyalendronateweeklyrisedronateandmonthlyibandronateregimensofbisphosphonates
AT mahajanshagun firstindianprospectiverandomizedcomparativestudyevaluatingadherenceandcomplianceofpostmenopausalosteoporoticpatientsfordailyalendronateweeklyrisedronateandmonthlyibandronateregimensofbisphosphonates
AT mahajanannil firstindianprospectiverandomizedcomparativestudyevaluatingadherenceandcomplianceofpostmenopausalosteoporoticpatientsfordailyalendronateweeklyrisedronateandmonthlyibandronateregimensofbisphosphonates
AT khajuriavijay firstindianprospectiverandomizedcomparativestudyevaluatingadherenceandcomplianceofpostmenopausalosteoporoticpatientsfordailyalendronateweeklyrisedronateandmonthlyibandronateregimensofbisphosphonates
AT gillanizahid firstindianprospectiverandomizedcomparativestudyevaluatingadherenceandcomplianceofpostmenopausalosteoporoticpatientsfordailyalendronateweeklyrisedronateandmonthlyibandronateregimensofbisphosphonates